A Trump administration rule will force pharmacy benefit managers to disclose fees and compensation details currently kept private, according to STAT. The move targets the opaque financial arrangements that have long shaped drug pricing in the US.
This matters for health insurers and pharmaceutical firms, as greater transparency could change how contracts are structured and how much is paid for medicines. It may also prompt further regulatory attention to pricing practices in the sector.
